Phaseline

Targets › DARS

DARS (Aspartate--tRNA ligase, cytoplasmic): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 4; Infectious disease; next expected readout Jun 2027.

Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. (UniProt, P14868)

Open in Phaseline: the race on DARS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MicuRxContezolid
Bacterial 70S ribosome inhibitor
DARSPhase 3Diabetic Foot Infection; Mycobacterium Avium Complex Pulmonary Disease; Pulmonary TuberculosisJun 2027

Conditions

Mycobacterium Avium Complex Pulmonary Disease (2) Diabetic Foot Infection (1) Pulmonary Tuberculosis (1)

Modalities

small molecule (1)

Companies

MicuRx (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.